Get Involved
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
Study Purpose
This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design every 3 weeks (Q3W) for up to 17 cycles/~1 year (each cycle = 21 days). Participants who complete the initial treatment of 17 cycles of pembrolizumab in Part 1 and experience disease recurrence may be eligible for re-challenge with pembrolizumab at the same dose and schedule of 200 mg Q3W (21-day cycles) for up to 35 cycles (up to ~2 years) in Part 2 in an open label design. Participants who complete the initial treatment of placebo and experience disease recurrence may be eligible to switch over to pembrolizumab 200 mg Q3W (21-day cycles) for up to 35 cycles (up to ~2 years) in Part 2 in an open label design. The primary hypothesis of this study is that pembrolizumab increases recurrence-free survival (RFS) compared to placebo. Per protocol, response/ progression or adverse events (AEs) during re-challenge/switch-over in Part 2 will not be counted towards the RFS outcome measure or safety outcome measures respectively.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 12 Years and Over |
| Gender | All |
Inclusion:
- - Has surgically resected and histologically/pathologically confirmed new diagnosis of Stage IIB or IIC cutaneous melanoma per American Joint Committee on Cancer (AJCC) 8th edition guidelines.
- - Has not been previously treated for melanoma beyond complete surgical resection.
- - Has ≤12 weeks between final surgical resection and randomization.
- - Has no evidence of metastatic disease on imaging as determined by investigator.
- - Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale or Lansky Play-Performance Scale (LPS) score ≥50 for participants ≤16 years old, or a Karnofsky Performance Scale (KPS) score ≥50 for participants >16 and <18 years old.
- - Has recovered adequately from toxicity and/or complications from surgery prior to study start.
- - Female participants must not be pregnant or breastfeeding, and must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment if they are women of childbearing potential (WOCBP) Exclusion: - Has a known additional malignancy that is progressing or has required active antineoplastic therapy (including hormonal) within the past 5 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy.
- - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.
- - WOCBP who has a positive urine pregnancy test within 72 hours prior to randomization.
- - Has received prior therapy with an anti-Programmed Cell Death Receptor 1 (PD-1), anti-Programmed Cell Death Receptor Ligand 1 (PD-L1) or anti-Programmed Cell Death Receptor Ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137) - Has received prior systemic anti-cancer therapy for melanoma including investigational agents.
- - Has received a live vaccine within 30 days prior to the first dose of study treatment.
- - Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
- - Has severe hypersensitivity (≥Grade 3) to any excipients of pembrolizumab.
- - Has an active autoimmune disease that has required systemic treatment in the past 2 years.
- - Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
- - Has an active infection requiring systemic therapy.
- - Has a known history of human immunodeficiency virus (HIV) infection.
- - Has a known history of hepatitis B (defined as hepatitis B surface antigen reactive) or known active hepatitis C virus (defined as hepatitis C virus ribonucleic acid [RNA] [qualitative] is detected) infection.
- - Has a history of active tuberculosis (Bacillus tuberculosis) - Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
- - Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT03553836 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 3 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
Merck Sharp & Dohme LLC |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Medical Director |
| Principal Investigator Affiliation | Merck Sharp & Dohme LLC |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
| Overall Status | Active, not recruiting |
| Countries | Australia, Belgium, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Poland, South Africa, Spain, Switzerland, United Kingdom, United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Melanoma |
| Study Website: | View Trial Website |
Arms
Experimental: Pembrolizumab
Participants receive 200 mg pembrolizumab (2 mg/kg for a maximum of 200 mg in pediatric participants) by intravenous (IV) infusion once every 3 weeks (Q3W; 21-day cycles) for up to 17 cycles (up to ~1 year) in Part 1. Participants who complete the initial treatment of 17 cycles of pembrolizumab and experience disease recurrence may be eligible for re-challenge with pembrolizumab at the same dose and schedule of 200 mg Q3W (21-day cycles) for up to 35 cycles (up to ~2 years) in Part 2.
Placebo Comparator: Placebo
Participants receive saline placebo by IV infusion Q3W (21-day cycles) for up to 17 cycles (up to ~1 year) in Part 1. Participants who complete the initial treatment of 17 cycles of placebo and experience disease recurrence may be eligible to switch over to pembrolizumab 200 mg Q3W (21-day cycles) for up to 35 cycles (up to ~2 years) in Part 2.
Interventions
Biological: - Pembrolizumab
Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
Other: - Placebo
Administered as an IV infusion every 3 weeks (Q3W)
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
University of Arizona Cancer Center ( Site 0121)
Tucson, Arizona, 85719
Status
Address
UCSD Moores Cancer Center ( Site 0133)
La Jolla, California, 92037
Status
Address
The Angeles Clinic and Research Institute ( Site 0029)
Los Angeles, California, 90025
Status
Address
UCLA Hematology & Oncology ( Site 0130)
Los Angeles, California, 90095
Status
Address
John Wayne Cancer Institute ( Site 0026)
Santa Monica, California, 90404
Status
Address
University of Colorado Cancer Center ( Site 0027)
Aurora, Colorado, 80045
Status
Address
Yale University ( Site 0035)
New Haven, Connecticut, 06511
Status
Address
Mayo Clinic Florida ( Site 0024)
Jacksonville, Florida, 32224
Status
Address
Moffitt McKinley Outpatient Center ( Site 0131)
Tampa, Florida, 33612
Status
Address
Winship Cancer Institute of Emory University ( Site 0046)
Atlanta, Georgia, 30322-1013
Status
Address
Northside Hospital ( Site 0115)
Atlanta, Georgia, 30341
Status
Address
Northwestern Medical Group ( Site 0135)
Chicago, Illinois, 60611
Status
Address
The University of Chicago Medical Center ( Site 0007)
Chicago, Illinois, 60637
Status
Address
Advocate Medical Group-Park Ridge ( Site 0025)
Park Ridge, Illinois, 60068
Status
Address
University of Iowa Hospital and Clinics ( Site 0001)
Iowa City, Iowa, 52242
Status
Address
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 0047)
Baltimore, Maryland, 21287
Status
Address
Massachusetts General Hospital ( Site 0126)
Boston, Massachusetts, 02114
Status
Address
Beth Israel Deaconess Medical Center ( Site 0141)
Boston, Massachusetts, 02215
Status
Address
Dana Farber Cancer Institute ( Site 0124)
Boston, Massachusetts, 02215
Status
Address
Karmanos Cancer Institute ( Site 0111)
Detroit, Michigan, 48201
Status
Address
Mayo Clinic [Rochester, MN] ( Site 0016)
Rochester, Minnesota, 55905
Status
Address
Siteman Cancer Center ( Site 0143)
Saint Louis, Missouri, 63110
Status
Address
Memorial Sloan Kettering ( Site 0006)
Harrison, New York, 10604
Status
Address
Laura and Isaac Perlmutter Cancer Center ( Site 0137)
New York, New York, 10016
Status
Address
Memorial Sloan Kettering Cancer Center ( Site 0142)
New York, New York, 10022
Status
Address
Mount Sinai Medical Center ( Site 0038)
New York, New York, 10029
Status
Address
University of Rochester ( Site 0019)
Rochester, New York, 14642
Status
Address
The Lindner Center for Research and Education at The Christ Hospital ( Site 0004)
Cincinnati, Ohio, 45219
Status
Address
Stephenson Cancer Center ( Site 0042)
Oklahoma City, Oklahoma, 73104
Status
Address
Oregon Health & Science University ( Site 0032)
Portland, Oregon, 97239
Status
Address
Children's Hospital of Pittsburgh UPMC ( Site 0144)
Pittsburgh, Pennsylvania, 15224
Status
Address
UPMC Hillman Cancer Centers ( Site 0043)
Pittsburgh, Pennsylvania, 15232
Status
Address
West Cancer Center - East Campus ( Site 0022)
Germantown, Tennessee, 38138
Status
Address
University of Tennessee Medical Center Knoxville ( Site 0116)
Knoxville, Tennessee, 37920
Status
Address
University of Texas-MD Anderson Cancer Center ( Site 0134)
Houston, Texas, 77030
Status
Address
Inova Schar Cancer Institute ( Site 0014)
Fairfax, Virginia, 22031
Status
Address
VCU Massey Cancer Center ( Site 0008)
Richmond, Virginia, 23298
Status
Address
Seattle Cancer Care Alliance ( Site 0044)
Seattle, Washington, 98109
Status
Address
University of Wisconsin Hospital and Clinics ( Site 0030)
Madison, Wisconsin, 53792
International Sites
Status
Address
Melanoma Institute Australia ( Site 0856)
North Sydney, New South Wales, 2065
Status
Address
Westmead Hospital ( Site 0853)
Westmead, New South Wales, 2145
Status
Address
Cairns Base Hospital ( Site 0859)
Cairns, Queensland, 4870
Status
Address
Tasman Oncology Research Pty Ltd ( Site 0858)
Southport, Queensland, 4215
Status
Address
Princess Alexandra Hospital ( Site 0857)
Woolloongabba, Queensland, 4102
Status
Address
Royal Adelaide Hospital ( Site 0861)
Adelaide, South Australia, 5000
Status
Address
Ashford Cancer Centre Research ( Site 0860)
Kurralta Park, South Australia, 5037
Status
Address
The Alfred Hospital ( Site 0852)
Melbourne, Victoria, 3004
Status
Address
Fiona Stanley Hospital ( Site 0851)
Murdoch, Western Australia, 6150
Status
Address
GZA Sint Augustinus ( Site 0259)
Wilrijk - Antwerpen, Antwerpen, 2610
Status
Address
Cliniques Universitaires Saint-Luc ( Site 0251)
Brussels, Bruxelles-Capitale, Region De, 1200
Status
Address
Institut Jules Bordet ( Site 0254)
Bruxelles, Bruxelles-Capitale, Region De, 1000
Status
Address
Jessa Ziekenhuis Campus Virga Jesse ( Site 0256)
Hasselt, Limburg, 3500
Status
Address
UZ Gent ( Site 0255)
Gent, Oost-Vlaanderen, 9000
Status
Address
UZ Leuven ( Site 0252)
Leuven, Vlaams-Brabant, 3000
Status
Address
Hospital Erasto Gaertner ( Site 0159)
Curitiba, Parana, 81520-060
Status
Address
Hospital de Caridade de Ijui ( Site 0156)
Ijui, Rio Grande Do Sul, 98700 000
Status
Address
Hospital Sao Vicente de Paulo ( Site 0158)
Passo Fundo, Rio Grande Do Sul, 99010-080
Status
Address
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 0154)
Porto Alegre, Rio Grande Do Sul, 90610-000
Status
Address
Fundacao Pio XII - Hospital de Cancer de Barretos ( Site 0155)
Barretos, Sao Paulo, 14784-400
Status
Address
Hospital de Clinicas de Rio Preto ( Site 0162)
Sao Jose Do Rio Preto - SP, Sao Paulo, 15090-000
Status
Address
Instituto Nacional do Cancer II ( Site 0160)
Rio de Janeiro, , 20220-410
Status
Address
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0151)
Sao Paulo, , 01246-000
Status
Address
Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0161)
Sao Paulo, , 01321-001
Status
Address
A.C. Camargo Cancer Center ( Site 0164)
Sao Paulo, , 01508-010
Status
Address
Cross Cancer Institute ( Site 0057)
Edmonton, Alberta, T6G 1Z2
Status
Address
CancerCare Manitoba ( Site 0053)
Winnipeg, Manitoba, R3E 0V9
Status
Address
Moncton Hospital - Horizon Health Network ( Site 0055)
Moncton, New Brunswick, E1C 6Z8
Status
Address
The Ottawa Hospital ( Site 0058)
Ottawa, Ontario, K1H 8L6
Status
Address
Sunnybrook Research Institute ( Site 0060)
Toronto, Ontario, M4N 3M5
Status
Address
Princess Margaret Cancer Centre ( Site 0059)
Toronto, Ontario, M5G 2M9
Status
Address
Hopital Maisonneuve Rosemont ( Site 0056)
Montreal, Quebec, H1T 2M4
Status
Address
Jewish General Hospital ( Site 0054)
Montreal, Quebec, H3T 1E2
Status
Address
McGill University Health Centre ( Site 0062)
Montreal, Quebec, H4A 3J1
Status
Address
CHU de Quebec - Hotel-Dieu de Quebec ( Site 0061)
Quebec, , G1R 2J6
Status
Address
Instituto Clinico Oncologico del Sur ( Site 0203)
Temuco, Araucania, 4810469
Status
Address
Fundacion Arturo Lopez Perez FALP ( Site 0200)
Santiago, Region M. De Santiago, 7500921
Status
Address
Pontificia Universidad Catolica de Chile ( Site 0201)
Santiago, Region M. De Santiago, 8330032
Status
Address
Sociedad Medica Aren y Bachero Limitada ( Site 0207)
Santiago, Region M. De Santiago, 8420383
Status
Address
Oncocentro ( Site 0204)
Vina del Mar, Valparaiso, 2520598
Status
Address
Centro Oncologico Antofagasta ( Site 0206)
Antofagasta, , 1240000
Status
Address
Hopital La Timone ( Site 0302)
Marseille, Bouches-du-Rhone, 13385
Status
Address
CHU Dijon Bourgogne ( Site 0320)
Dijon, Cote-d Or, 21000
Status
Address
CHU de Bordeaux- Hopital Saint Andre ( Site 0304)
Bordeaux, Gironde, 33075
Status
Address
Institut Claudius Regaud IUCT Oncopole ( Site 0306)
Toulouse, Haute-Garonne, 31059
Status
Address
Hopital Ambroise Pare Boulogne ( Site 0316)
Boulogne-Billancourt, Hauts-de-Seine, 92100
Status
Address
CHU Montpellier. ( Site 0312)
Montpellier, Herault, 34295
Status
Address
Centre Eugene Marquis ( Site 0305)
Rennes, Ille-et-Vilaine, 35042
Status
Address
CHU Angers ( Site 0321)
Angers, Maine-et-Loire, 49933
Status
Address
CHU de Reims ( Site 0307)
Reims, Marne, 51100
Status
Address
CHRU Lille - Hopital Claude Huriez ( Site 0301)
Lille, Nord, 59037
Status
Address
C.H.U. Lyon Sud ( Site 0303)
Pierre Benite, Rhone, 69495
Status
Address
CHU Amiens Picardie Hopital Nord ( Site 0317)
Amiens, Somme, 80054
Status
Address
Institut Gustave Roussy ( Site 0300)
Villejuif, Val-de-Marne, 94805
Status
Address
Hopital Saint Louis ( Site 0322)
Paris, , 75475
Status
Address
Universitaetsklinikum in Mannheim ( Site 0351)
Mannheim, Baden-Wurttemberg, 68135
Status
Address
Universitaetsklinikum Tuebingen ( Site 0353)
Tuebingen, Baden-Wurttemberg, 72076
Status
Address
Klinikum der Ludwig-Maximilians-Universitaet Muenchen ( Site 0357)
Muenchen, Bayern, 80337
Status
Address
Klinikum Nuernberg Nord ( Site 0355)
Nuernberg, Bayern, 90419
Status
Address
Klinikum der Universitaet in Wuerzburg ( Site 0356)
Wuerzburg, Bayern, 97080
Status
Address
Elbe Klinikum Buxtehude ( Site 0354)
Buxtehude, Niedersachsen, 21614
Status
Address
Medizinische Hochschule Hannover ( Site 0358)
Hannover, Niedersachsen, 30625
Status
Address
Klinik und Poliklinik fuer Dermatologie Venerologie und Allergologie ( Site 0361)
Essen, Nordrhein-Westfalen, 45147
Status
Address
Universitaetsklinikum Schleswig-Holstein Campus Kiel ( Site 0359)
Kiel, Schleswig-Holstein, 24105
Status
Address
SRH Wald-Klinikum Gera GmbH ( Site 0360)
Gera, Thuringen, 07548
Status
Address
Universitaetsklinikum Hamburg Eppendorf (UKE) ( Site 0352)
Hamburg, , 20246
Status
Address
Soroka Medical Center ( Site 0653)
Beer Sheva, Southern, 8457108
Status
Address
Sourasky Medical Center ( Site 0656)
Tel Aviv, Tell Abib, 6423906
Status
Address
HaEmek Medical Center ( Site 0655)
Afula, , 1834111
Status
Address
Rambam Medical Center ( Site 0654)
Haifa, , 3109601
Status
Address
Hadassah Ein Kerem Medical Center ( Site 0651)
Jerusalem, , 9112001
Status
Address
Chaim Sheba Medical Center. ( Site 0652)
Ramat Gan, , 5262000
Status
Address
Shamir Medical Center-Assaf Harofeh ( Site 0657)
Zerifin, , 70300
Status
Address
Istituto Scientifico Romagnolo per Studio e Cura Tumori IRST ( Site 0403)
Meldola, Forli-Cesena, 47014
Status
Address
IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 0406)
Bari, , 70124
Status
Address
ASST Papa Giovanni XXIII ( Site 0402)
Bergamo, , 24127
Status
Address
IRCCS A.O.U. San Martino - IST ( Site 0404)
Genova, , 16132
Status
Address
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0408)
Milano, , 20133
Status
Address
Istituto Nazionale Tumori Fondazione Pascale ( Site 0400)
Napoli, , 80131
Status
Address
IRCCS Istituto Oncologico Veneto ( Site 0407)
Padova, , 35128
Status
Address
IDI - Istituto Dermopatico dell'Immacolata ( Site 0405)
Roma, , 00167
Status
Address
Azienda Ospedaliero Universitaria Senese ( Site 0401)
Siena, , 53100
Status
Address
National Cancer Center Hospital ( Site 0910)
Tokyo, , 104-0045
Status
Address
Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 0769)
Bydgoszcz, Kujawsko-pomorskie, 85-796
Status
Address
Pratia MCM Krakow ( Site 0773)
Krakow, Malopolskie, 30-510
Status
Address
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0751)
Warszawa, Mazowieckie, 02-781
Status
Address
Instytut Pomnik Centrum Zdrowia Dziecka ( Site 0759)
Warszawa, Mazowieckie, 04-730
Status
Address
Kliniczny Szpital Wojewodzki Nr 1 ( Site 0758)
Rzeszow, Podkarpackie, 35-055
Status
Address
Uniwersyteckie Centrum Kliniczne ( Site 0770)
Gdansk, Pomorskie, 80-402
Status
Address
Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 0754)
Bielsko-Biala, Slaskie, 43-300
Status
Address
Uniwersyteckie Centrum Kliniczne Slaskiego Uniwersytetu Medycznego ( Site 0757)
Katowice, Slaskie, 40-514
Status
Address
LIFTMED ( Site 0765)
Rybnik, Slaskie, 44-200
Status
Address
Szpital Kliniczny im. Heliodora Swiecickiego Uniwers Medyczn ( Site 0753)
Poznan, Wielkopolskie, 60-780
Status
Address
Cancer Care Langenhoven Drive Oncology Centre ( Site 0812)
Port Elizabeth, Eastern Cape, 6045
Status
Address
Sandton Oncology Medical Group PTY LTD ( Site 0801)
Johannesburg, Gauteng, 2196
Status
Address
Charlotte Maxeke Johannesburg Academic Hospital ( Site 0811)
Parktown, Gauteng, 2196
Status
Address
Wilgers Oncology Centre ( Site 0806)
Pretoria, Gauteng, 0081
Status
Address
MPOC ( Site 0803)
Pretoria, Gauteng, 0181
Status
Address
Cancercare ( Site 0810)
Cape Town, Limpopo, 7700
Status
Address
Cape Town Oncology Trials Pty Ltd ( Site 0807)
Kraaifontein, Western Cape, 7570
Status
Address
Onkologikoa - Instituto Oncologico de San Sebastian ( Site 0457)
San Sebastian, Gipuzkoa, 20014
Status
Address
Hospital General Universitario de Valencia ( Site 0451)
Valencia, Valenciana, Comunitat, 46014
Status
Address
Hospital General Universitari Vall d Hebron ( Site 0456)
Barcelona, , 08035
Status
Address
Hospital Clinic de Barcelona ( Site 0452)
Barcelona, , 08036
Status
Address
Hospital General Universitario Gregorio Maranon ( Site 0454)
Madrid, , 28009
Status
Address
Hospital Universitario Virgen Macarena ( Site 0455)
Sevilla, , 41009
Status
Address
Universitaetsspital Basel ( Site 0554)
Basel, Basel-Stadt, 4031
Status
Address
Universitaetsspital Bern ( Site 0552)
Bern, Berne, 3010
Status
Address
Hopitaux Universitaires de Geneve HUG ( Site 0556)
Geneva, Geneve, 1211
Status
Address
Kantonsspital Graubuenden ( Site 0555)
Chur, Grisons, 7000
Status
Address
Kantonsspital St. Gallen ( Site 0559)
St. Gallen, Sankt Gallen, 9007
Status
Address
Oncological Institute of Southern Switzerland ( Site 0557)
Bellinzona, Ticino, 6500
Status
Address
Centre Hospitalier Universitaire Vaudois ( Site 0553)
Lausanne, Vaud, 1011
Status
Address
Hopital du Valais ( Site 0558)
Sion, Wallis, 1951
Status
Address
Universitaetsspital Zuerich ( Site 0551)
Zuerich, Zurich, 8091
Status
Address
Addenbrooke's Hospital in Cambridge ( Site 0600)
Cambridge, Cambridgeshire, CB2 0QQ
Status
Address
Guy s & St Thomas NHS Foundation Trust ( Site 0601)
London, London, City Of, SE1 9RT
Status
Address
Royal Marsden Hospital - Fulham Road London ( Site 0613)
London, London, City Of, SW3 6JJ
Status
Address
The Royal Marsden NHS Foundation Trust. ( Site 0612)
Sutton, Surrey, SM2 5PT
Status
Address
Christie NHS Foundation Trust ( Site 0604)
Manchester, , M20 4GJ
